Last updated August 15, 2026
Key finding
HbA1c decreased by 0.54% compared to placebo (p < 0.0001).
This study evaluated the efficacy and safety of fixed-dose combinations of Sitagliptin and Empagliflozin in patients with inadequately controlled Type 2 Diabetes, showing significant reductions in HbA1c and body weight.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of fixed-dose combinations of Sitagliptin and Empagliflozin in patients with inadequately controlled Type 2 Diabetes, showing significant reductions in HbA1c and body weight.
These findings are clinically significant as they suggest that combining Sitagliptin and Empagliflozin can provide an effective treatment option for patients struggling to control their Type 2 Diabetes, potentially leading to better health outcomes and improved quality of life.
Limited generalizability due to specific population characteristics. Short duration of the study may not reflect long-term effects. Potential for unmeasured confounders affecting outcomes.
Published in
Publication details and source links for this paper.
Soo L, Tae NK, Ji OM, et al. Efficacy and Safety of Sitagliptin/Empagliflozin Fixed-Dose Combinations in Patients with Inadequately Controlled Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2026;28(6):4847-4859. doi:10.1111/dom.70669
HbA1c decreased by 0.54% compared to placebo (p < 0.0001).
Fasting Plasma Glucose decreased by 28.16 mg/dL compared to placebo (p < 0.0001).
Body weight decreased by 2.82 kg compared to placebo (p < 0.0001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors and Body weight, Diastolic blood pressure, Fasting Plasma Glucose (FPG), and 3 more.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
6
Evidence pairs
826
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Dipeptidyl peptidase-4 inhibitors → Body weight
Dipeptidyl peptidase-4 inhibitors → Body weight
Dipeptidyl peptidase-4 inhibitors → Diastolic blood pressure
Dipeptidyl peptidase-4 inhibitors → Diastolic blood pressure
Dipeptidyl peptidase-4 inhibitors → Fasting Plasma Glucose (FPG)
Dipeptidyl peptidase-4 inhibitors → Fasting Plasma Glucose (FPG)
Dipeptidyl peptidase-4 inhibitors → Insulin resistance
Dipeptidyl peptidase-4 inhibitors → Insulin resistance
Dipeptidyl peptidase-4 inhibitors → Systolic blood pressure
Dipeptidyl peptidase-4 inhibitors → Systolic blood pressure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and HbA1c, DPP-4 Inhibitors and Body Weight.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on DPP-4 Inhibitors
Contributes to DPP-4 Inhibitors evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
5 results
4 results
5 results
5 results
4 results
Generated from the study's connected evidence using Evidence Intelligence™.
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
DPP-4 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
DPP-4 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.
Limitations
DPP-4 Inhibitors may improve Insulin Resistance.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Insulin resistance
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
